Kiniksa Pharmaceuticals International (KNSA) Income from Continuing Operations (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Income from Continuing Operations data on file, last reported at 25432000.0 in Q2 2026.

• Quarterly Income from Continuing Operations rose 42.62% year-over-year to 25432000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 80658000.0 (up 1583.88% YoY) and the FY2025 annual result came in at 59005000.0, up 236.61% from the prior year.
• Income from Continuing Operations advanced to 25432000.0 in Q2 2026, from 22592000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 224093000.0 in Q3 2022 to a low of 49244000.0 in Q4 2023.
• A 5-year average of 15048277.78 and a median of 2315500.0 in 2024 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 833.67% — and 2023, when it tumbled 155.63%.
• Tracing KNSA's Income from Continuing Operations over 5 years: stood at 88528000.0 in 2022, then slumped by 155.63% to 49244000.0 in 2023, then jumped by 81.95% to 8888000.0 in 2024, then soared by 259.75% to 14199000.0 in 2025, then surged by 79.11% to 25432000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 25432000.0 (Q2 2026), 22592000.0 (Q1 2026), and 14199000.0 (Q4 2025), per Business Quant data.